Targeting the heat shock factor 1 by RNA interference: A potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer

Cancer Research

Volumn 66, Issue 15, 2006, Pages 7678-7685

  Rossi, Antonio ^a   Ciafrè, Stefania ^a   Balsamo, Mirna ^b   Pierimarchi, Pasquale ^a   Santoro, M Gabriella ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL ISOLATION; CELL PROTECTION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENE TARGETING; GENE VECTOR; HUMAN; HUMAN CELL; HYPERTHERMIA; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; UTERINE CERVIX CANCER;

APOPTOSIS; CISPLATIN; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; FEMALE; GENE SILENCING; HEAT-SHOCK PROTEINS; HELA CELLS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 33747875267     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4282     Document Type: Article

References (43)

1. Morimoto RI, Santoro MG. Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nat Biotechnol 1998;16:833-8.
2. Morimoto RI. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 1998;12:3788-96.
3. Kline MP, Morimoto RI. Repression of the heat shock factor 1 transcriptional activation domain is modulated by constitutive phosphorylation. Mol Cell Biol 1997;17:2107-15.
4. Pirkkala L, Nykanen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J 2001;15:1118-31.
5. Yoo HY, Chang MS, Rho HM. The activation of the rat copper/zinc superoxide dismutase gene by hydrogen peroxide through the hydrogen peroxide-responsive element and by paraquat and heat shock through the same heat shock element. J Biol Chem 1999;274:23887-92.
6. Vilaboa NE, Galan A, Troyano A, de Blas E, Aller P. Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 2000;275:24970-6.
7. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999;248:30-43.
8. Helmbrecht K, Zeise E, Rensing L. Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 2000;33:341-65.
9. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92:1564-72.
10. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004;23:2907-18.
11. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487-97.
12. Takahashi I, Emi Y, Hasuda S, Kakeji Y, Maehara Y, Sugimachi K. Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors. Surgery 2002;131:S78-84.
13. de Wit R, van der Zee J, van der Burg ME, et al. A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix. Br J Cancer 1999;80:1387-91.
14. Parsell DA, Taulien J, Lindquist S. The role of heat-shock proteins in thermotolerance. Philos Trans R Soc Lond B Biol Sci 1993;339:279-85.
15. Calderwood SK, Asea A. Targeting HSP70-induced thermotolerance for design of thermal sensitizers. Int J Hyperthermia 2002;18:597-608.
16. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003;22:9041-7.
17. Sreedhar AS, Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 2004;101:227-57.
18. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
19. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000;403:103-8.
20. Rossi A, Elia G, Santoro MG. Activation of the heat shock factor 1 by serine protease inhibitors. An effect associated with nuclear factor-κB inhibition. J Biol Chem 1998;273:16446-52.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
22. Lee RC, Feinbaum RL, Ambras V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
23. Wyllie AH, Morris RG, Smith AL, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984;142:67-77.
24. Mathew A, Mathur SK, Jolly C, Fox SG, Kim S, Morimoto RI. Stress-specific activation and repression of heat shock factors 1 and 2. Mol Cell Biol 2001;21:7163-71.
25. Cotto J, Fox S, Morimoto R. HSF1 granules: a novel stress-induced nuclear compartment of human cells. J Cell Sci 1997;110:2925-34.
26. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
27. Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist 2002;7 Suppl 5:36-45.
28. Serkies K, Jassem J. Chemotherapy in the primary treatment of cervical carcinoma. Crit Rev Oncol Hematol 2005;54:197-208.
29. Dahl O. Interaction of heat and drugs in vitro and in vivo. In: Seegenschmiedt MH, Fessenden P, Vernon CC, editors. Thermoradiotherapy and thermochemotherapy. Berlin: Springer; 1995. p. 103-21.
30. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-8.
31. Rossi A, Elia G, Santoro MG. Inhibition of nuclear factor κB by prostaglandin A1: an effect associated with heat shock transcription factor activation. Proc Natl Acad Sci U S A 1997;94:746-50.
32. Fortier E, Belote JM. Temperature-dependent gene silencing by an expressed inverted repeat in Drosphila. Genesis 2000;26:240-4.
33. Szittya G, Silhavy D, Molnar A, et al. Low temperature inhibits RNA silencing-mediated defence by the control of siRNA generation. EMBO J 2003;22:633-40.
34. Kameda T, Ikegami K, Liu Y, Terada K, Sugiyama T. A hypothermic- temperature-sensitive gene silencing by the mammalian RNAi. Biochem Biophys Res Commun 2004;315:599-602.
35. Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jaattela M. Members of the heat shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 2005;19:570-82.
36. Cai L, Zhu JD. The tumor-selective over-expression of the human Hsp70 gene is attributed to the aberrant controls at both initiation and elongation levels of transcription. Cell Res 2003;13:93-109.
37. Wu G, Osada M, Guo Z, et al. ΔNp63α up-regulates the Hsp70 gene in human cancer. Cancer Res 2005;65:758-66.
38. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005;65:10536-44.
39. van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355:1119-25.
40. McCaffrey P. Warming up to a triple therapy for cervical cancer. Lancet Oncol 2005;6:642.
41. Westermann AM, Jones EL, Schem BC, et al. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer 2005;104:763-70.
42. DiPaolo JA, Alvarez-Salas LM. Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opin Biol Ther 2004;4:1251-64.
43. Jiang M, Rubbi CP, Milner J. Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides 2004;14:239-48.